Carboxyalkyl Chitosan
OwnerMickaël Chausson, Pierre Douette +4inventors
InventorsMickaël Chausson, Pierre Douette, Sandrine Emilia Gautier, Philippe Vaesen, Houtaï Choumane, Guillermo Rocasalbas
Life of this patent
Estimating the term…
Abstract
The present invention relates to a carboxyalkyl chitosan, compositions comprising same, a process for manufacturing same, and various applications thereof, in particular in the field of therapy, rheumatology, ophthalmology, aesthetic medicine, plastic surgery, internal surgery, dermatology or cosmetics.
Claims37
A method of ophthalmic treatment, said method comprising administering a carboxyalkyl chitosan to at least one eye of a subject in need thereof, wherein said carboxyalkyl chitosan comprises glucosamine units, N-acetyl-glucosamine units, and glucosamine units substituted by a carboxyalkyl group, wherein the chitosan is of fungal origin, wherein said carboxyalkyl chitosan has a degree of substitution by the carboxyalkyl group that is greater than 50%, expressed as the number of moles of the substituent carboxyalkyl group relative to the number of moles of total units, wherein said carboxyalkyl chitosan is has a degree of acetylation ranging from 30% to 80%, expressed in number of moles of N-acetyl-glucosamine units relative to the number of moles of total units, and wherein said carboxyalkyl chitosan is a N,O-carboxyalkyl chitosan.
An ophthalmic composition, wherein said ophthalmic composition comprises an aqueous solution, insert, film or bandage in gel or solid form, comprising a carboxyalkyl chitosan comprising glucosamine units, N-acetyl-glucosamine units, and glucosamine units substituted by a carboxyalkyl group, wherein said carboxyalkyl chitosan comprises glucosamine units, N-acetyl-glucosamine units, and glucosamine units substituted by a carboxyalkyl group, wherein the chitosan is of fungal origin, wherein said carboxyalkyl chitosan has a degree of substitution by the carboxyalkyl group that is greater than 50%, expressed as the number of moles of the substituent carboxyalkyl group relative to the number of moles of total units, wherein said carboxyalkyl chitosan is has a degree of acetylation ranging from 30% to 80%, expressed in number of moles of N-acetyl-glucosamine units relative to the number of moles of total units, and wherein said carboxyalkyl chitosan is a N,O-carboxyalkyl chitosan.
The ophthalmic formulation of claim 122, wherein said ophthalmic formulation has a viscosity of less than 10 mPa·s in conditions of ocular movement.
Dependencies are inferred from the claim text.